Argenx Se (ARGX) Operating Expenses (2016 - 2026)
Argenx Se (ARGX) posted Operating Expenses of -$919.0 million for Q1 2026, up 3.72% on a QoQ basis from -$954.5 million in Q4 2025, and down 37.57% year-over-year from -$1.5 billion in Q1 2025.
Argenx Se (ARGX) Operating Expenses (2016 - 2026) Analysis & Trends
Argenx Se's Operating Expenses history runs 11 years deep, the most recent figure standing at -$919.0 million for Q1 2026.
- Quarterly Operating Expenses fell 37.57% year-over-year to -$919.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.9 billion (down 48.68% YoY) and the FY2025 annual result came in at $3.2 billion, up 40.49% from the prior year.
- Operating Expenses was -$919.0 million for Q1 2026 at Argenx Se, up from -$954.5 million in the prior quarter.
- Across five years, Operating Expenses topped out at $766.1 million in Q2 2025 and bottomed at -$954.5 million in Q4 2025.
- A 5-year average of -$341.1 million and a median of -$420.4 million in 2023 frame the typical range for Operating Expenses.
- Annual changes were most pronounced in 2023 — Operating Expenses jumped 247.51% — and 2025, when it plunged 240.1%.
- Argenx Se's Operating Expenses stood at -$296.5 million in 2022, then tumbled by 87.65% to -$556.5 million in 2023, then fell by 18.28% to -$658.2 million in 2024, then tumbled by 45.03% to -$954.5 million in 2025, then increased by 3.72% to -$919.0 million in 2026.
- Business Quant data shows ARGX's Operating Expenses at -$919.0 million in Q1 2026, -$954.5 million in Q4 2025, and -$805.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -28.01 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 15.76 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 1.10 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.85 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 2.96 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | 32.68 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | -919.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 445.22 Mn |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | 898.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -919.00 Mn |
| Dec 31, 2025 | -954.54 Mn |
| Sep 30, 2025 | -805.14 Mn |
| Jun 30, 2025 | 766.13 Mn |
| Mar 31, 2025 | -668.00 Mn |
| Dec 31, 2024 | -658.18 Mn |
| Sep 30, 2024 | 574.69 Mn |
| Jun 30, 2024 | -534.89 Mn |
| Mar 31, 2024 | -505.93 Mn |
| Dec 31, 2023 | -556.46 Mn |
| Sep 30, 2023 | -420.43 Mn |
| Jun 30, 2023 | 383.13 Mn |
| Mar 31, 2023 | -333.62 Mn |
| Dec 31, 2022 | -296.55 Mn |
| Sep 30, 2022 | -355.13 Mn |
| Jun 30, 2022 | -259.73 Mn |
| Mar 31, 2022 | -254.21 Mn |
| Dec 31, 2021 | -264.60 Mn |
| Sep 30, 2021 | -220.06 Mn |
| Jun 30, 2021 | -224.93 Mn |